(Q34174176)

31 July 2017

1 reference

title

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. (English)

1 reference

31 July 2017

1 reference

Pomerantz RJ

1

1 reference

31 July 2017

publication date

1 February 2001

1 reference

Biomedicine and Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

55

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

7-15

1 reference

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Antiretroviral drugs and the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Re-emergence of HIV after stopping therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Treatment of HIV infection with cytoreductive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

Residual HIV-1 disease in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2900016-0

7 January 2021

10.1016/S0753-3322(00)00016-0

Identifiers

DOI

1 reference

31 July 2017

1 reference